Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified
Conditions
Interventions
Intervention1: Group A: Study Group (Unani Drug): Safoof-i Mohazzil with Arq-i Zeera to be taken orally 3.5 gm BD and 75ml BD respectively for 8 weeks.
Control Intervention1: Group B: Active Control G
Sponsors
National Research Institute of Unani Medicine for Skin Disorders
Eligibility
Inclusion criteria
Inclusion criteria: (i). Participants of any gender aged 30 t0 60 years. (ii) Participants having any one or more of the following lipid abnormalities in blood: a. Total Cholestrol more than or equal to 200 mg/dl b. LDL Cholesterol more than or equal to 130 mg/dl c. HDL Cholesterol less than 40 mg/dl d. Serum Triglycerides 150-400 mg/dl (iii) Body Mass Index 23-40 kg/m2
Exclusion criteria
Exclusion criteria: i. Participants aged 60 years. ii. Serum Triglyceride 400 mg/dL iii. Body Mass Index (BMI) 40 kg/m2 iv. Participants having hypertension & diabetes v. Significant Pulmonary/ Cardiovascular/ Hepatorenal Dysfunction vi. Known cases of malignancy, HIV infection, AIDS, etc. vii. Any other clinical condition that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the trial. viii. Pregnancy and Lactation ix. Known allergy, sensitivity or intolerance to the study drug or any of its ingredients. x. Participants with active alcohol intake and/or drug abuse. xi. Participants not willing to sign the ICF and to attend treatment schedule regularly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid Profile Timepoint: At baseline and end of trial | — |
Secondary
| Measure | Time frame |
|---|---|
| Haemogram Urine R/E & M/E LFTs RFTs ECGTimepoint: At baseline, 2nd week and end of trial | — |
Countries
India
Contacts
Public ContactProf Qamar Uddin
National Research Institute of Unani Medicine for Skin Disorders
Outcome results
None listed